Date: 2014-11-17
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Valneva (France - Austria) undisclosed animal vaccine manufacturer (Japan)
Therapeutic area: Veterinary medicine
Type agreement: licensing R&D
Action mechanism: EB66® cell line is a highly efficient platform for vaccine production. It is derived from duck embryonic stem cells and today represents a compelling alternative to the use of chicken eggs for large scale manufacturing of human and veterinary vaccines. To date, Valneva has more than 35 research and commercial agreements with the world’s largest pharmaceutical companies to utilize its EB66® technology. The first human vaccine using EB66® technology received marketing approval in 2014 and the first veterinary vaccine in 2012.
Disease:
Details: * On November 17, 2014, Valneva announced that it has signed two new research agreements in Japan to develop human and veterinary vaccines in Valneva’s EB66® cell line. The first license agreement was signed with a global pharmaceutical company, which provides products and services in more than 50 countries throughout the world, and a second license agreement was signed with one of the largest animal vaccine manufacturers in Japan, both to evaluate the potential of EB66® cells to produce new vaccines. To date, Valneva has more than 35 agreements encompassing over 50 products in development using the EB66® cell line with companies throughout the world.
Financial terms: The company names and the financial terms of the agreements were not disclosed due to confidentiality but do include annual fees and pre-agreed financial terms for future product commercialization.
Latest news:
